PMID,Title,Journal,Year
39846709,Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.,Infectious disease reports,2025
39173063,Cross-relationship between COVID-19 infection and anti-obesity products efficacy and incidence of side effects: A cross-sectional study.,PloS one,2024
37759668,Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19.,Biology,2023
37720167,The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.,Health science reports,2023
35815766,[Benefits of telematic monitoring for weight loss in overweight and obese patients in times of confinement].,Nutricion hospitalaria,2022
35406751,GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation.,Cells,2022
33440950,Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report.,Annals of palliative medicine,2021
32900588,"Anti-inflammatory properties of antidiabetic drugs: A ""promised land"" in the COVID-19 era?",Journal of diabetes and its complications,2020
